These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18977144)

  • 41. PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells.
    Huang SH; Xiong M; Chen XP; Xiao ZY; Zhao YF; Huang ZY
    Oncol Rep; 2008 Sep; 20(3):567-72. PubMed ID: 18695907
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold.
    Giannini G; Battistuzzi G; Vesci L; Milazzo FM; De Paolis F; Barbarino M; Guglielmi MB; Carollo V; Gallo G; Artali R; Dallavalle S
    Bioorg Med Chem Lett; 2014 Jan; 24(2):462-6. PubMed ID: 24388690
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.
    Bryant HE; Helleday T
    Nucleic Acids Res; 2006; 34(6):1685-91. PubMed ID: 16556909
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The expression of poly(ADP-ribose) polymerase during differentiation-linked DNA replication reveals that it is a component of the multiprotein DNA replication complex.
    Simbulan-Rosenthal CM; Rosenthal DS; Hilz H; Hickey R; Malkas L; Applegren N; Wu Y; Bers G; Smulson ME
    Biochemistry; 1996 Sep; 35(36):11622-33. PubMed ID: 8794742
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of proliferation and invasiveness of ovarian cancer C13* cells by a poly(ADP-ribose) polymerase inhibitor and the role of nuclear factor-κB.
    Wang Z; Li Y; Lv S; Tian Y
    J Int Med Res; 2013 Oct; 41(5):1577-85. PubMed ID: 24097829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased poly(ADP-ribose) formation in cisplatin-resistant rat ovarian tumor cells.
    Chen G; Zeller WJ
    Anticancer Res; 1994; 14(4A):1461-7. PubMed ID: 7979172
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells.
    D'Onofrio G; Tramontano F; Dorio AS; Muzi A; Maselli V; Fulgione D; Graziani G; Malanga M; Quesada P
    Biochem Pharmacol; 2011 Jan; 81(2):194-202. PubMed ID: 20875401
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation.
    Li H; Hu Y; Wang X; He G; Xu Y; Zhu Q
    Bioorg Med Chem; 2016 Oct; 24(19):4731-4740. PubMed ID: 27561983
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of poly (ADP-ribosyl) polymerase (PARP) inhibitor on cisplatin resistance & proliferation of the ovarian cancer C13* cells.
    Zhang J; Kan Y; Tian Y; Wang Z; Zhang J
    Indian J Med Res; 2013 Mar; 137(3):527-32. PubMed ID: 23640560
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure.
    Canan Koch SS; Thoresen LH; Tikhe JG; Maegley KA; Almassy RJ; Li J; Yu XH; Zook SE; Kumpf RA; Zhang C; Boritzki TJ; Mansour RN; Zhang KE; Ekker A; Calabrese CR; Curtin NJ; Kyle S; Thomas HD; Wang LZ; Calvert AH; Golding BT; Griffin RJ; Newell DR; Webber SE; Hostomsky Z
    J Med Chem; 2002 Nov; 45(23):4961-74. PubMed ID: 12408707
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer.
    Steffen JD; Tholey RM; Langelier MF; Planck JL; Schiewer MJ; Lal S; Bildzukewicz NA; Yeo CJ; Knudsen KE; Brody JR; Pascal JM
    Cancer Res; 2014 Jan; 74(1):31-7. PubMed ID: 24189460
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DNA damage-induced inhibition of rRNA synthesis by DNA-PK and PARP-1.
    Calkins AS; Iglehart JD; Lazaro JB
    Nucleic Acids Res; 2013 Aug; 41(15):7378-86. PubMed ID: 23775790
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-cancer action of 4-iodo-3-nitrobenzamide in combination with buthionine sulfoximine: inactivation of poly(ADP-ribose) polymerase and tumor glycolysis and the appearance of a poly(ADP-ribose) polymerase protease.
    Bauer PI; Mendeleyeva J; Kirsten E; Comstock JA; Hakam A; Buki KG; Kun E
    Biochem Pharmacol; 2002 Feb; 63(3):455-62. PubMed ID: 11853696
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy.
    Yusoh NA; Ahmad H; Gill MR
    ChemMedChem; 2020 Nov; 15(22):2121-2135. PubMed ID: 32812709
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of poly(ADP-ribose) polymerase with nuclear subfractions catalyzed with sodium tetrathionate and hydrogene peroxide crosslinks.
    Desnoyers S; Kirkland JB; Poirier GG
    Mol Cell Biochem; 1996 Jun; 159(2):155-61. PubMed ID: 8858566
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts.
    Kedar PS; Stefanick DF; Horton JK; Wilson SH
    Mol Cancer Res; 2012 Mar; 10(3):360-8. PubMed ID: 22246237
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transcriptomics reveals
    Stolzenburg LR; Ainsworth B; Riley-Gillis B; Pakozdi T; Ammar A; Ellis PA; Wilsbacher JL; Ramathal CY
    Oncotarget; 2022; 13():1-12. PubMed ID: 35018214
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent Study of Dual HDAC/PARP Inhibitor for the Treatment of Tumor.
    Lu H; Bai L; Zhou Y; Lu Y; Jiang Z; Shi J
    Curr Top Med Chem; 2019; 19(12):1041-1050. PubMed ID: 31161991
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of hyperthermia and doxorubicin on nucleoid sedimentation and poly (ADP-ribose) polymerase activity in L1210 cells.
    Daugherty JP; Simpson TA; Mullins DW
    Cancer Chemother Pharmacol; 1988; 21(3):229-32. PubMed ID: 3129205
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PARP inhibitors: an interesting pathway also for non-small cell lung cancer?
    Levra MG; Olaussen KA; Novello S; Soria JC
    Curr Pharm Des; 2014; 20(24):3875-82. PubMed ID: 24191958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.